MX2022009254A - Dosificacion y metodos para tratar la hipertension arterial pulmonar. - Google Patents
Dosificacion y metodos para tratar la hipertension arterial pulmonar.Info
- Publication number
- MX2022009254A MX2022009254A MX2022009254A MX2022009254A MX2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A
- Authority
- MX
- Mexico
- Prior art keywords
- rodatristat
- ethyl
- sub
- combination
- pah
- Prior art date
Links
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 title abstract 10
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 6
- 229940121489 rodatristat Drugs 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002207 metabolite Substances 0.000 abstract 3
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 abstract 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 abstract 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 abstract 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 abstract 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 abstract 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 abstract 2
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 abstract 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 abstract 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 abstract 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 abstract 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229960002414 ambrisentan Drugs 0.000 abstract 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 abstract 1
- 229960003065 bosentan Drugs 0.000 abstract 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 abstract 1
- 230000008406 drug-drug interaction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003116 impacting effect Effects 0.000 abstract 1
- 229960001039 macitentan Drugs 0.000 abstract 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 229960003841 selexipag Drugs 0.000 abstract 1
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960005032 treprostinil Drugs 0.000 abstract 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968651P | 2020-01-31 | 2020-01-31 | |
| PCT/IB2021/000046 WO2021152398A1 (en) | 2020-01-31 | 2021-01-29 | Dosages and methods for treating pulmonary arterial hypertension with rodatristat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009254A true MX2022009254A (es) | 2022-09-07 |
Family
ID=75143674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009254A MX2022009254A (es) | 2020-01-31 | 2021-01-29 | Dosificacion y metodos para tratar la hipertension arterial pulmonar. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230074252A1 (enExample) |
| EP (1) | EP4096633A1 (enExample) |
| JP (1) | JP2023512025A (enExample) |
| KR (1) | KR20220156813A (enExample) |
| CN (1) | CN115379825A (enExample) |
| AU (1) | AU2021212355A1 (enExample) |
| CA (1) | CA3165432A1 (enExample) |
| MX (1) | MX2022009254A (enExample) |
| WO (1) | WO2021152398A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210105343A (ko) | 2018-11-16 | 2021-08-26 | 알타반트 사이언시스 게엠베하 | 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법 |
| WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
| WO2023079486A1 (en) * | 2021-11-03 | 2023-05-11 | Altavant Sciences Gmbh | Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| KR20210102887A (ko) * | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
-
2021
- 2021-01-29 CN CN202180021555.2A patent/CN115379825A/zh not_active Withdrawn
- 2021-01-29 US US17/759,700 patent/US20230074252A1/en not_active Abandoned
- 2021-01-29 AU AU2021212355A patent/AU2021212355A1/en not_active Abandoned
- 2021-01-29 WO PCT/IB2021/000046 patent/WO2021152398A1/en not_active Ceased
- 2021-01-29 KR KR1020227030098A patent/KR20220156813A/ko not_active Withdrawn
- 2021-01-29 CA CA3165432A patent/CA3165432A1/en active Pending
- 2021-01-29 MX MX2022009254A patent/MX2022009254A/es unknown
- 2021-01-29 EP EP21713735.5A patent/EP4096633A1/en not_active Withdrawn
- 2021-01-29 JP JP2022546019A patent/JP2023512025A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3165432A1 (en) | 2021-08-05 |
| EP4096633A1 (en) | 2022-12-07 |
| US20230074252A1 (en) | 2023-03-09 |
| CN115379825A (zh) | 2022-11-22 |
| KR20220156813A (ko) | 2022-11-28 |
| WO2021152398A1 (en) | 2021-08-05 |
| AU2021212355A1 (en) | 2022-08-18 |
| JP2023512025A (ja) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8034808B2 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
| CA2691914A1 (en) | Pharmaceutical compositions and methods of treating dry eye disorders | |
| CA2540858A1 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | |
| GB0423653D0 (en) | Pharmaceutical compounds | |
| WO2007056075A3 (en) | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | |
| IL191027A0 (en) | Treatment method | |
| Drinane et al. | Sofosbuvir and ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient | |
| CN101031305A (zh) | 类风湿性关节炎的预防和/或治疗药物 | |
| JP2023512025A5 (enExample) | ||
| Ramani et al. | Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension | |
| Shen et al. | Synergistic down-regulation of signal transduction and cytotoxicity by tiazofurin and quercetin in human ovarian carcinoma cells | |
| WO2020157577A8 (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| Aribindi et al. | Investigational pharmacological agents for the treatment of ARDS | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| WO2007120726B1 (en) | Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml | |
| WO2008150565A3 (en) | Ranolazine for elevated brain-type natriuretic peptide | |
| JP2023512025A (ja) | 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法 | |
| CA2620065A1 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| Ting et al. | Preliminary results of a phase 2a dose optimization study of ASLAN003 (DHODH inhibitor) in acute myeloid leukemia (AML) patients who are ineligible for standard therapy; early signs of activity | |
| CA2504665A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| de Tejada Echanojáuregui et al. | Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus | |
| Maher et al. | Taxanes and capecitabine in combination: rationale and clinical results | |
| Sohn et al. | Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration | |
| Jenkins et al. | Public Interest Comment: Interagency Efforts to Develop the American Conservation and Stewardship Atlas | |
| Gutierrez | Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? |